June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ocular tolerability of a ciclosporin eye drop based on PAD™ technology
Author Affiliations & Notes
  • Frederic Gomez
    MC2 Therapeutics, Hoersholm, Denmark
  • Morten Praestegaard
    MC2 Therapeutics, Hoersholm, Denmark
  • Fraser Steele
    MC2 Therapeutics, Hoersholm, Denmark
  • Footnotes
    Commercial Relationships   Frederic Gomez, MC2 Therapeutics (C); Morten Praestegaard, MC2 Therapeutics (E); Fraser Steele, MC2 Therapeutics (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 484. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Frederic Gomez, Morten Praestegaard, Fraser Steele; Ocular tolerability of a ciclosporin eye drop based on PAD™ technology. Invest. Ophthalmol. Vis. Sci. 2017;58(8):484.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : MC2 Therapeutics is developing PADciclo™, a new and optimized formulation of ciclosporin (CsA) based on PAD™ technology currently in clinical development for the treatment of moderate to severe dry eye. This new formulation contains less surfactants and is aimed to improve tolerability of CsA in dry eye. In these studies, ocular tolerance of PADciclo™ was determined up to 6 months in New Zealand White albinos rabbits.

Methods : The PADciclo™ eye drop targets ocular inflammation which is well-known as one of the underlying causes of dry eye. Two studies were conducted. In a 28-day ocular tolerance study, animals received four ocular administrations per day of PADciclo™ vehicle or PADciclo™ 0.1% CsA, separated by intervals of approximately three hours. In a 6-month ocular tolerance study, animals received two ocular administrations per day of PADciclo™ vehicle or PADciclo™ 0.1% CsA. For both studies, clinical signs, corneal sensitivity, body weights and food and water consumption were monitored.

Results : This is the first time that PADciclo™ tolerance data in animals are reported. PADciclo™ 0.1% CsA and PADciclo™ vehicle administered 4 times daily for 28 days or 2 times daily for 26 weeks in albino rabbits were macroscopically and microscopically very well tolerated. There were no treatment- or administration-related effects on body weight, clinical observations, food consumption, ophthalmic examinations, macroscopic observations at necropsy, or histopathology.

Conclusions : The presented studies confirm that the PADciclo™ vehicle and PADciclo™ 0.1% CsA administered 4 times daily for 28 days or 2 times daily for 26 weeks is safe and very well tolerated by the rabbit eye.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×